UA72882C2 - Спосіб лікування нестабільності чи надактивності сечового міхура, фармацевтична композиція з регульованим вивільненням та використання толтеродину - Google Patents

Спосіб лікування нестабільності чи надактивності сечового міхура, фармацевтична композиція з регульованим вивільненням та використання толтеродину

Info

Publication number
UA72882C2
UA72882C2 UA2000052950A UA200052950A UA72882C2 UA 72882 C2 UA72882 C2 UA 72882C2 UA 2000052950 A UA2000052950 A UA 2000052950A UA 200052950 A UA200052950 A UA 200052950A UA 72882 C2 UA72882 C2 UA 72882C2
Authority
UA
Ukraine
Prior art keywords
tolterodine
controlled release
pharmaceutical composition
related compound
formulation
Prior art date
Application number
UA2000052950A
Other languages
English (en)
Russian (ru)
Inventor
Лісбет Нілвебрант
Бенгт Халлен
Біргітта Олссон
Ян Стрьомбом
Бу Креілгор
Якобсен Лене Оруп
Улла Хек
Хелле Крістенсен
Торкел Грен
Андерс Рінгберг
Мартін Вікберг
Original Assignee
Фармація Енд Апджон Аб
Фармация Энд Апджон Аб.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA72882(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Фармація Енд Апджон Аб, Фармация Энд Апджон Аб. filed Critical Фармація Енд Апджон Аб
Publication of UA72882C2 publication Critical patent/UA72882C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Спосіб та фармацевтична композиція для лікування нестабільності чи надактивності сечового міхура, який полягає в тому, що пацієнту, який потребує такого лікування, призначають толтеродин, його 5-гідроксиметиловий метаболіт чи рацемат, що відповідає толтеродину, чи їх фармацевтично прийнятну сіль у фармацевтично ефективній кількості у композиції з регульованим вивільненням, забезпечуючи середній флуктуаційний індекс активної частини чи частин у сироватці не вище приблизно 2,0, переважно не вище приблизно 1,0, причому флуктуаційний індекс, ФІ, визначено як де Смакc та Смін – відповідно максимальна та мінімальна концентрації активної частини чи частин, - площа під кривою залежності концентрації у сироватці, та - інтервал споживання, через що у сироватці підтримується, по суті, постійний рівень активної частини чи частин принаймні протягом 24 годин.
UA2000052950A 1998-08-27 1999-08-26 Спосіб лікування нестабільності чи надактивності сечового міхура, фармацевтична композиція з регульованим вивільненням та використання толтеродину UA72882C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Publications (1)

Publication Number Publication Date
UA72882C2 true UA72882C2 (uk) 2005-05-16

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2000052950A UA72882C2 (uk) 1998-08-27 1999-08-26 Спосіб лікування нестабільності чи надактивності сечового міхура, фармацевтична композиція з регульованим вивільненням та використання толтеродину

Country Status (31)

Country Link
US (1) US6770295B1 (uk)
EP (2) EP2153825A1 (uk)
CN (1) CN1239152C (uk)
AP (1) AP1529A (uk)
AR (1) AR029311A1 (uk)
AT (1) ATE487471T1 (uk)
AU (1) AU745190B2 (uk)
BG (1) BG65168B1 (uk)
CA (1) CA2311755C (uk)
CY (1) CY1111088T1 (uk)
CZ (1) CZ302630B6 (uk)
DE (1) DE69942928D1 (uk)
DK (1) DK1039882T3 (uk)
EA (1) EA002720B1 (uk)
GE (1) GEP20043354B (uk)
HK (1) HK1034664A1 (uk)
HU (1) HUP0100437A3 (uk)
ID (1) ID25824A (uk)
IL (1) IL136294A (uk)
IS (1) IS2976B (uk)
ME (1) ME00850B (uk)
MY (1) MY127946A (uk)
NO (1) NO329830B1 (uk)
NZ (1) NZ504618A (uk)
OA (1) OA11636A (uk)
PT (1) PT1039882E (uk)
SI (1) SI1039882T1 (uk)
SK (1) SK287111B6 (uk)
TR (1) TR200001998T1 (uk)
UA (1) UA72882C2 (uk)
WO (1) WO2000012069A1 (uk)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
SK6412002A3 (en) * 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
WO2003039524A1 (en) * 2001-11-09 2003-05-15 Pharmacia Ab Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE60332387D1 (de) * 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
CA2514022C (en) * 2003-01-22 2010-07-13 Pfizer Health Ab Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
US7410978B2 (en) 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
JP4771956B2 (ja) 2003-11-04 2011-09-14 スパーナス ファーマシューティカルズ インコーポレイテッド バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2604052C (en) * 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
JP5869745B2 (ja) 2006-02-03 2016-02-24 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー ２５−ヒドロキシビタミンｄ２及び２５−ヒドロキシビタミンｄ３によるビタミンｄ不足及び欠乏の治療
US20070248670A1 (en) * 2006-04-21 2007-10-25 Van Den Heuvel Dennie J M Tolterodine beads
EP3659608A1 (en) 2006-06-21 2020-06-03 Opko Ireland Global Holdings, Ltd. Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
ES2956794T3 (es) 2007-04-25 2023-12-28 Eirgen Pharma Ltd Liberación controlada de 25-hidroxivitamina D
EP3335712A1 (en) 2007-04-25 2018-06-20 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
EP2173329A1 (en) * 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CN102046812A (zh) 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
KR102125424B1 (ko) 2010-03-29 2020-06-22 사이토크로마 인코포레이티드 부갑상선 수준을 낮추기 위한 방법 및 조성물
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20130195957A1 (en) * 2010-08-03 2013-08-01 Hisamitsu Pharmaceutical Co., Inc. Patch and method for enhancing adhesion force of the same
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
BR112018069727A2 (pt) 2016-03-28 2019-02-05 Opko Ireland Global Holdings Ltd métodos de tratamento com vitamina d

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
WO1993023025A1 (en) * 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
AU7994694A (en) * 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
JP2000515525A (ja) * 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
EP0927034A1 (en) * 1996-09-19 1999-07-07 American Home Products Corporation Method of treating urinary incontinence

Also Published As

Publication number Publication date
CA2311755A1 (en) 2000-03-09
ID25824A (id) 2000-11-09
MY127946A (en) 2007-01-31
IS2976B (is) 2017-07-15
BG65168B1 (bg) 2007-05-31
NO20002977D0 (no) 2000-06-09
HK1034664A1 (en) 2001-11-02
EP2153825A1 (en) 2010-02-17
GEP20043354B (en) 2004-04-13
CZ302630B6 (cs) 2011-08-10
AR029311A1 (es) 2003-06-25
PT1039882E (pt) 2011-01-03
BG104476A (en) 2000-12-29
CN1287484A (zh) 2001-03-14
WO2000012069A1 (en) 2000-03-09
CY1111088T1 (el) 2015-06-11
SI1039882T1 (sl) 2011-01-31
AU5891899A (en) 2000-03-21
US6770295B1 (en) 2004-08-03
EA200000468A1 (ru) 2000-12-25
NO329830B1 (no) 2011-01-03
CZ20001924A3 (cs) 2001-04-11
IL136294A0 (en) 2001-05-20
AP1529A (en) 2006-01-03
EA002720B1 (ru) 2002-08-29
AP2000001823A0 (en) 2000-06-30
DK1039882T3 (da) 2011-01-24
OA11636A (en) 2004-09-03
HUP0100437A2 (hu) 2002-05-29
NZ504618A (en) 2002-09-27
SK7492000A3 (en) 2001-02-12
EP1039882A1 (en) 2000-10-04
ME00850B (me) 2008-08-07
CN1239152C (zh) 2006-02-01
EP1039882B1 (en) 2010-11-10
ATE487471T1 (de) 2010-11-15
DE69942928D1 (de) 2010-12-23
NO20002977L (no) 2000-06-09
SK287111B6 (sk) 2009-12-07
TR200001998T1 (tr) 2001-01-22
HUP0100437A3 (en) 2002-08-28
CA2311755C (en) 2010-03-23
IL136294A (en) 2004-02-08
IS5537A (is) 2000-06-15
AU745190B2 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
UA72882C2 (uk) Спосіб лікування нестабільності чи надактивності сечового міхура, фармацевтична композиція з регульованим вивільненням та використання толтеродину
CA2215329A1 (en) Colorectal chemoprotective composition and method for preventing colorectal cancer
CA2341063A1 (en) Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
NZ303372A (en) Use of (s)-oxybutynin and (s)-desethyloxybutynin to treat urinary incontinence
HK1054196A1 (en) Pharmaceutical formulation containing tolterodine and its use
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
AU5876596A (en) Oral dosage and method for treating painful conditions of th e oral cavity
MXPA04003866A (es) Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
HU9303748D0 (en) Composition of l-dopa-esters
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
CA2251966A1 (en) Transdermally administered dextromethorphan as antitussive agent
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
MY124465A (en) Reduction of infarct volume using citicoline
GR3036071T3 (en) Use od moxonidine for the Treatment of neuropathic pain
HK1038310A1 (en) Compositions and methods for treating intracellular infections.
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
GEP20043231B (en) Resorcinol Composition
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
WO1992017065A3 (en) Method of inhibiting fibrosis
NZ268110A (en) Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage
WO2001068076A8 (en) D-enantiomer of dfmo and methods of use thereof for treating cancer
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor